A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial - the PRADA trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
25 Mar 2019
Historique:
received: 04 05 2018
accepted: 01 03 2019
entrez: 27 3 2019
pubmed: 27 3 2019
medline: 4 9 2019
Statut: epublish

Résumé

Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term despite long-term control having been acknowledged as one of the most important core outcome domains to be targeted in atopic dermatitis trials. Safe add-on therapies, rigorously evaluated for long-term control of the disease, are therefore needed. Phototherapy and vitamin D supplementation are both good candidates. This is a multicenter, national, randomized, superiority, crossover trial testing add-on phototherapy (one winter under spaced sessions of phototherapy and one winter under observation) among subjects receiving standard care (i.e., TAT). On the same population, we will test the long-term control provided by oral supplementation of vitamin D versus placebo in a randomized, superiority, double-blind, parallel-group trial. The primary outcomes are (1) repeat measures of the PO-SCORAD severity score over 1 year and (2) cumulate consumption of TAT (number of tubes) during the winter. They will be tested following a hierarchical testing procedure. The secondary outcomes will be measures repeated over 2 years of investigator-based severity scores, patient-reported severity and quality of life scores, serum vitamin D levels, weeks during which the disease is well-controlled, inter-visit cumulate consumption of TAT, and synthetic patient-reported satisfaction at the end of each winter. This study includes two separate 2-year pragmatic trials designed to evaluate the efficacy of vitamin D supplementation and pro-active phototherapy for primary care atopic dermatitis patients receiving TAT on long-term control of disease activity. The experimental design enables the study of both interventions and exploration of the interaction between vitamin D and phototherapy. A pragmatic trial is particularly suited to the assessment of long-term control. This study explores the possibility of new and safe therapeutic strategies for the control of long-term atopic dermatitis, and is an example of efficacy research that is unlikely to be sponsored by industrialists. A potentially effective low-cost therapeutic strategy for long-term control is essential for patients and public health. ClinicalTrials.gov Identifier: NCT02537509 , first received: 1 September 2015.

Sections du résumé

BACKGROUND BACKGROUND
Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term despite long-term control having been acknowledged as one of the most important core outcome domains to be targeted in atopic dermatitis trials. Safe add-on therapies, rigorously evaluated for long-term control of the disease, are therefore needed. Phototherapy and vitamin D supplementation are both good candidates.
METHODS METHODS
This is a multicenter, national, randomized, superiority, crossover trial testing add-on phototherapy (one winter under spaced sessions of phototherapy and one winter under observation) among subjects receiving standard care (i.e., TAT). On the same population, we will test the long-term control provided by oral supplementation of vitamin D versus placebo in a randomized, superiority, double-blind, parallel-group trial. The primary outcomes are (1) repeat measures of the PO-SCORAD severity score over 1 year and (2) cumulate consumption of TAT (number of tubes) during the winter. They will be tested following a hierarchical testing procedure. The secondary outcomes will be measures repeated over 2 years of investigator-based severity scores, patient-reported severity and quality of life scores, serum vitamin D levels, weeks during which the disease is well-controlled, inter-visit cumulate consumption of TAT, and synthetic patient-reported satisfaction at the end of each winter.
DISCUSSION CONCLUSIONS
This study includes two separate 2-year pragmatic trials designed to evaluate the efficacy of vitamin D supplementation and pro-active phototherapy for primary care atopic dermatitis patients receiving TAT on long-term control of disease activity. The experimental design enables the study of both interventions and exploration of the interaction between vitamin D and phototherapy. A pragmatic trial is particularly suited to the assessment of long-term control. This study explores the possibility of new and safe therapeutic strategies for the control of long-term atopic dermatitis, and is an example of efficacy research that is unlikely to be sponsored by industrialists. A potentially effective low-cost therapeutic strategy for long-term control is essential for patients and public health.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov Identifier: NCT02537509 , first received: 1 September 2015.

Identifiants

pubmed: 30909923
doi: 10.1186/s13063-019-3276-9
pii: 10.1186/s13063-019-3276-9
pmc: PMC6434814
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Cholecalciferol 1C6V77QF41

Banques de données

ClinicalTrials.gov
['NCT02537509']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

184

Références

Annu Rev Public Health. 2000;21:193-221
pubmed: 10884952
Health Technol Assess. 2000;4(37):1-191
pubmed: 11134919
BMJ. 2003 Jun 21;326(7403):1367
pubmed: 12816824
Ann Epidemiol. 2004 Apr;14(4):296-303
pubmed: 15066610
N Engl J Med. 2008 Apr 3;358(14):1483-94
pubmed: 18385500
J Invest Dermatol. 2008 Dec;128(12):2880-7
pubmed: 18580964
Allergy. 2008 Jul;63(7):742-50
pubmed: 18592619
J Dermatol Sci. 2009 May;54(2):76-87
pubmed: 19303745
J Clin Epidemiol. 2009 May;62(5):464-75
pubmed: 19348971
CMAJ. 2009 May 12;180(10):1001-3
pubmed: 19372437
J Invest Dermatol. 2011 Jan;131(1):67-73
pubmed: 20739951
Br J Dermatol. 2011 Feb;164(2):415-28
pubmed: 20819086
Br J Dermatol. 2011 May;164(5):1078-82
pubmed: 21087229
N Engl J Med. 2011 May 5;364(18):1685-7
pubmed: 21542739
N Engl J Med. 2011 May 5;364(18):1695-707
pubmed: 21542741
Allergy. 2012 Mar;67(3):296-301
pubmed: 22171613
PLoS One. 2012;7(7):e39803
pubmed: 22808063
J Allergy Clin Immunol. 2012 Oct;130(4):925-31.e4
pubmed: 22947344
Pediatr Dermatol. 2013 May-Jun;30(3):359-63
pubmed: 23289912
Arch Dermatol Res. 2014 Apr;306(3):279-86
pubmed: 23982630
J Allergy Clin Immunol. 2013 Nov;132(5):1132-8
pubmed: 24094544
Br J Dermatol. 2014 Mar;170(3):501-13
pubmed: 24116934
J Stat Softw. 2013 Sep;54(10):
pubmed: 24403868
Allergy. 2014 Jan;69(1):3-16
pubmed: 24417229
J Allergy Clin Immunol. 2014 Jun;133(6):1615-25.e1
pubmed: 24655575
Ann Dermatol Venereol. 2014 Apr;141(4):265-71
pubmed: 24703640
Int J Epidemiol. 2014 Oct;43(5):1645-55
pubmed: 24756878
J Am Acad Dermatol. 2014 Aug;71(2):327-49
pubmed: 24813298
Br J Dermatol. 2014 Dec;171(6):1318-25
pubmed: 24980543
Ann Dermatol. 2015 Feb;27(1):10-4
pubmed: 25673925
Lancet. 2016 Mar 12;387(10023):1109-1122
pubmed: 26377142
J Am Acad Dermatol. 2016 Oct;75(4):681-687.e11
pubmed: 27544489
Nutrients. 2016 Dec 03;8(12):
pubmed: 27918470
J Invest Dermatol. 2017 Jun;137(6):1380-1384
pubmed: 28202402
Allergy. 2018 Jun;73(6):1284-1293
pubmed: 29319189
N Engl J Med. 1997 Jan 23;336(4):309-15
pubmed: 8995096
J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):125-38
pubmed: 9893196

Auteurs

Catherine Droitcourt (C)

Univ Rennes, Rennes, France. catherine.droitcourt@chu-rennes.fr.
Department of Dermatology, University Hospital Center of Rennes, Pontchaillou Hospital, 2 rue Henri le Guilloux, 35000, Rennes, France. catherine.droitcourt@chu-rennes.fr.
INSERM, CIC 1414, 35000, Rennes, France. catherine.droitcourt@chu-rennes.fr.
EA 7449 REPERES "Pharmaco-epidemiology and Health Services Research", Univ Rennes, 35000, Rennes, France. catherine.droitcourt@chu-rennes.fr.

Sébastien Barbarot (S)

Department of Dermatology, University Hospital Center of Nantes, 44000, Nantes, France.

Annabel Maruani (A)

Department of Dermatology, University Hospital Center of Tours, 37000, Tours, France.

Laure Darrieux (L)

Department of Dermatology, Hospital Center of Saint-Brieuc, 22000, Saint-Brieuc, France.

Laurent Misery (L)

Department of Dermatology, University Hospital Center of Brest, 29000, Brest, France.

Emilie Brenaut (E)

Department of Dermatology, University Hospital Center of Brest, 29000, Brest, France.

Henri Adamski (H)

Department of Dermatology, University Hospital Center of Rennes, Pontchaillou Hospital, 2 rue Henri le Guilloux, 35000, Rennes, France.

Cécile Chabbert (C)

Department of Dermatology, Hospital Center of Perigueux, 24000, Perigueux, France.

Annie Vermersch (A)

Department of Dermatology, Hospital Center of Valenciennes, 62000, Valenciennes, France.

Marie Weiborn (M)

Department of Dermatology, Hospital Center of Valenciennes, 62000, Valenciennes, France.

Julien Seneschal (J)

Department of Dermatology, University Hospital Center of Bordeaux, 33000, Bordeaux, France.

Alain Taïeb (A)

Department of Dermatology, University Hospital Center of Bordeaux, 33000, Bordeaux, France.

Patrice Plantin (P)

Department of Dermatology, Hospital Center of Quimper, 29000, Quimper, France.

Hervé Maillard (H)

Department of Dermatology, Hospital Center of Le Mans, 72000, Angers, France.

Alice Phan (A)

Department of Dermatology, University Hospital Center of Lyon, 69000, Lyon-Bron, France.

François Skowron (F)

Department of Dermatology, Hospital Center of Valence, 26000, Valence, France.

Manuelle Viguier (M)

Department of Dermatology, University Hospital Center of Reims, 51000, Reims, France.

Delphine Staumont-Salle (D)

Department of Dermatology, University Hospital Center of Lille, 59000, Lille, France.

Audrey Nosbaum (A)

Department of Dermatology, University Hospital Center of Lyon, 69000, Lyon Sud, France.

Angèle Soria (A)

Department of Dermatology and Allergology, University Hospital Center of Paris-Tenon, 75020, Paris, France.

Annick Barbaud (A)

Department of Dermatology and Allergology, University Hospital Center of Paris-Tenon, 75020, Paris, France.

Emmanuel Oger (E)

Univ Rennes, Rennes, France.
EA 7449 REPERES "Pharmaco-epidemiology and Health Services Research", Univ Rennes, 35000, Rennes, France.

Alain Dupuy (A)

Univ Rennes, Rennes, France.
Department of Dermatology, University Hospital Center of Rennes, Pontchaillou Hospital, 2 rue Henri le Guilloux, 35000, Rennes, France.
EA 7449 REPERES "Pharmaco-epidemiology and Health Services Research", Univ Rennes, 35000, Rennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH